1 research outputs found
Enhancement of the Targeting Capabilities of the Paclitaxel-Loaded Pluronic Nanoparticles with a Glycol Chitosan/Heparin Composite
An enhancement of tumor-targeting capability was demonstrated
with
paclitaxel (PTX)-loaded Pluronic nanoparticles (NPs) with immobilized
glycol chitosan and heparin. The PTX-loaded Pluronic NPs were prepared
as described in our previous report by means of a temperature-induced
phase transition in a mixture of Pluronic F-68 and liquid polyethylene
glycol (PEG; molecular weight: 400) containing PTX. The liquid PEG
is used as the solubilizer of PTX, and Pluronic F-68 is the polymer
that encapsulates the PTX. The glycol chitosan and heparin were immobilized
on the surface of the Pluronic NPs in an aqueous medium, and a powdery
form of the glycol chitosan/heparin immobilized Pluronic NPs (composite
NPs) was obtained by freeze-drying. Field emission scanning electron
microscopy and a particle size analyzer were used to observe the morphology
and size distribution of the prepared NPs. To apply the composite
NPs as a delivery system for the model anticancer drug PTX, the release
pattern and pharmacokinetic parameters were observed, and the tumor
growth was monitored by injecting the composite NPs into the tail
veins of tumor-bearing mice. An enhancement of tumor-targeting capability
of NPs was verified by using noninvasive live animal imaging technology
to observe the time-dependent excretion profile, the in vivo biodistribution,
circulation time, and the tumor-targeting capability of composite
NPs